JUMPCAN(SH:600566) IPO早知道·2026-02-03 06:10Core Viewpoint - The article discusses the strategic collaboration between Puxi Pharmaceutical and Jichuan Pharmaceutical Group for the development and commercialization of Pumeixin nasal spray, a novel JAK inhibitor aimed at treating allergic rhinitis, which is expected to be the world's first nasal spray JAK inhibitor [2][3]. Group 1: Collaboration Details - Puxi Pharmaceutical has entered into a strategic cooperation agreement with Jichuan Pharmaceutical, with a maximum transaction value of 100 million RMB, including an upfront payment of 40 million RMB and milestone payments up to 60 million RMB [2]. - Jichuan Pharmaceutical will obtain exclusive commercialization rights for the product in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [2]. Group 2: Product Development and Market Potential - Pumeixin is a self-developed JAK1/2 inhibitor with complete intellectual property rights, specifically designed for allergic rhinitis treatment, and is anticipated to provide a groundbreaking treatment option for patients [3]. - The product has completed multiple Phase I/II clinical studies and is currently undergoing Phase III clinical research after receiving approval from the Chinese National Medical Products Administration (NMPA) [3]. Group 3: Company Focus and Pipeline - Puxi Pharmaceutical specializes in innovative drugs for immune/inflammatory diseases, with a product pipeline that includes treatments for dermatology, respiratory, and ophthalmology conditions [3]. - Core products include Pumeixin gel for atopic dermatitis, Pumeixin nasal spray for allergic rhinitis, PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG-040 eye drops for glaucoma, all of which have global leading potential as innovative drugs [3].